Compare AbbVie Inc (ABBV) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Eos Energy Enterprises Inc — how do they compare? AbbVie Inc trades at $254.16 (market cap $449.91B), while Eos Energy Enterprises Inc trades at $4.51 (market cap $1.68B). The key difference: AbbVie Inc is far larger — about 267.8× Eos Energy Enterprises Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| ABBV | EOSE | |
|---|---|---|
Market Cap | $449.91B | $1.68B |
Sector | Health | Energy |
52-Week High | $261.07 | $19.19 |
52-Week Low | $184.85 | $4.40 |
Enterprise Value | $513.38B | $1.91B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EOSE trades at $5.06, down 3.25% today, amid a bearish technical signal despite a recent Q1 2026 earnings beat. The company shows rapid revenue growth but deep losses, with a net income margin of -296.13% in 2026. Recent news highlights progress in its Frontier Power USA venture and new supply agreements, yet cash flow remains negative from operations, relying on financing.
The outlook is mixed: analyst consensus is a Buy with a $8.33 price target, signaling potential upside, but high execution risk persists given substantial losses and a debt-to-asset ratio of 91.87%. Investors face volatility from operational cash burn against growth initiatives in the competitive energy storage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
